GTBP Stock Analysis: Buy, Sell, or Hold?
GTBP - GT Biopharma Inc. Common Stock
$0.43
0.01 (3.34%)
▲
5d:
-16.34%
30d:
+8.78%
90d:
-3.59%
WAIT
LOW Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When GTBP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: GTBP is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: GTBP is down 16.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: GTBP is currently trading at $0.43, which is considered fair relative to its 30-day fair value range of $0.41 to $0.47.
Technical Outlook: Technically, GTBP is in a downtrend. Immediate support is located at $0.37, while resistance sits at $0.49. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+597.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GTBP is in a downtrend. Immediate support is located at $0.37, while resistance sits at $0.49. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.00 (+597.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.41 -
$0.47
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 597.7% below Wall St target ($3.00)
- WARNING: Recommendation downgraded due to -16.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.41 -
$0.47
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.37
Resistance Level
$0.50
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.59
Wall Street Target
$3.00
(+597.7%)
Share & Embed Analysis
Last updated: June 28, 2026 4:27 PM ET
Data refreshes hourly during market hours. Next update: 5:27 PM
Data refreshes hourly during market hours. Next update: 5:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GTBP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 58 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1041 | 59 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
